Pelage Pharmaceuticals Raises $120M in Series B Co-Led by ARCH and GV

Deal Summary

Pelage Pharmaceuticals closed a $120 million Series B to advance its lead topical program PP405 for hair follicle stem cell reactivation. The round was co-led by ARCH Venture Partners and GV, with participation from Main Street Advisors, Visionary Ventures, and YK Bioventures.